Journal
RHEUMATOLOGY
Volume 62, Issue SI3, Pages SI260-SI270Publisher
OXFORD UNIV PRESS
DOI: 10.1093/rheumatology/kead489
Keywords
inflammatory arthritis; rheumatoid arthritis; comorbidity; multimorbidity; inflammation
Categories
Ask authors/readers for more resources
Early identification and management of multimorbidity in patients with rheumatic and musculoskeletal diseases (RMDs) is critical for disease outcome and treatment response.
Early identification and management of multimorbidity in patients with rheumatic and musculoskeletal diseases (RMDs), such as RA, is an integral, but often neglected, aspect of care. The prevalence and incidence of conditions such as osteoporosis, cardiovascular disease, pulmonary disease and malignancies, often co-existing with RA, continues to have significant implications for the management of this patient group. Multimorbidity in RMDs can be associated with inflammatory disease activity and target organ damage. Lifestyle factors, such as smoking and inactivity, further contribute to the burden of disease. Inflammation is the underlying factor, not just in RA but also many comorbidities. The current framework of a treat-to-target approach focuses on achieving early remission and inflammatory activity suppression. We describe how the comorbidity burden in people with RMDs impacts on disease outcome and treatment response. The importance of addressing comorbidity at an early stage and adopting a patient centred approach is critical in modern practice.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available